Want to see HK:1652 full AI Analyst Report?
1652 Stock Chart & Stats
HK$0.80
-HK$0.03(-4.41%)
At close: 4:00 PM EST
HK$0.80
-HK$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeHK$0.30 - HK$1.75
Previous CloseN/A
Volume70.00K
Average Volume (3M)1.23M
Market Cap
HK$779.34M
Enterprise ValueHK$865.00M
Total Cash (Recent Filing)HK$83.88M
Total Debt (Recent Filing)HK$324.34M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding739,301,000
10 Day Avg. Volume642,000
30 Day Avg. Volume1,233,253
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)1.48
Price to Sales (P/S)1.94
P/FCF Ratio7.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Operating Cash Flow StrengthConsistent positive operating cash flow in 2024–2025 underpins the business's ability to fund working capital and sustain operations without immediate reliance on external financing. Durable cash generation supports reinvestment and gives management time to fix profitability despite historical volatility.
Top-line Recovery In 2025A strong revenue rebound in 2025 signals restored demand or successful commercial actions, creating a platform for margin recovery and scale benefits. If sustained, higher revenues can amortize fixed costs and enable a structural earnings turnaround over several quarters.
Serviceable Balance Sheet With Positive EquityPositive equity and a stable asset base provide financial resilience, allowing access to debt or equity markets and protecting operating continuity. This balance-sheet footing supports strategic options and buffers operational setbacks while profitability is being restored.
Bears Say
Sustained Multi-year LossesSustained losses from 2022–2025 indicate structural profitability issues that erode retained earnings and constrain reinvestment. Persistent negative earnings weaken ROE and limit internal funding for R&D or commercial expansion, making a durable recovery dependent on consistent margin improvement.
Margin Compression In 2025Notable gross-margin compression in 2025 reduces cash conversion and makes it harder to translate revenue growth into profits. Structural margin pressure requires sustained pricing power or cost control to reverse; without that, revenue rebounds may not produce lasting earnings improvement.
Increased Leverage Reduces FlexibilityLeverage rising to near parity increases fixed obligations and reduces financial flexibility. Higher debt levels constrain the company's ability to invest or absorb shocks, and magnify downside risk if profitability fails to improve, making strategic maneuvering more costly.
Fusen Pharmaceutical Co., Ltd. News
1652 FAQ
What was Fusen Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Fusen Pharmaceutical Co., Ltd. lowest stock price was HK$0.30 and its highest was HK$1.75 in the past 12 months.
What is Fusen Pharmaceutical Co., Ltd.’s market cap?
Fusen Pharmaceutical Co., Ltd.’s market cap is HK$779.34M.
When is Fusen Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Fusen Pharmaceutical Co., Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 34 days.
How were Fusen Pharmaceutical Co., Ltd.’s earnings last quarter?
Fusen Pharmaceutical Co., Ltd. released its earnings results on Mar 31, 2026. The company reported HK$0.017 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.017.
Is Fusen Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Fusen Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Fusen Pharmaceutical Co., Ltd. pay dividends?
Fusen Pharmaceutical Co., Ltd. pays a Notavailable dividend of HK$0.004 which represents an annual dividend yield of N/A. See more information on Fusen Pharmaceutical Co., Ltd. dividends here
What is Fusen Pharmaceutical Co., Ltd.’s EPS estimate?
Fusen Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusen Pharmaceutical Co., Ltd. have?
Fusen Pharmaceutical Co., Ltd. has 739,301,000 shares outstanding.
What happened to Fusen Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Fusen Pharmaceutical Co., Ltd. reported an EPS of HK$0.017 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Fusen Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1652
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fusen Pharmaceutical Co., Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.80%
Trailing 12-Months
Company Description
Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Company Limited operates as an investment holding enterprise, primarily engaged in the manufacturing and distribution of a diverse range of pharmaceutical products across the People's Republic of China. Its extensive product portfolio includes specific cold remedies based on Shuanghuanglian, offered as both oral solutions and injections, alongside medications like flunarizine hydrochloride capsules and compound ferrous sulfate granules. The company further provides Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. Beyond these, Fusen actively researches, develops, produces, and markets a variety of proprietary Chinese medicines and modern Western pharmaceuticals, targeting conditions such as colds, fevers, cardiovascular ailments, and anemia. Additionally, the firm offers business management and advisory services. Fusen Pharmaceutical Company Limited was established in 2003 and is headquartered in Nanyang, China.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―